EPISODE · May 8, 2024 · 53 MIN
Dr. David Latshaw, Ph.D. - Co-Founder and CEO, BioPhy - Providing Practical AI For Drug Development
from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. David Latshaw
Send us Fan MailDr. David Latshaw, Ph.D. is Co-Founder and CEO of BioPhy ( https://www.biophy.ai/ ), a Philadelphia based artificial intelligence company which has developed a set of platforms that provide quantitative metrics to drug company partners about what drugs and clinical trials will ultimately succeed. Dr. Latshaw is a computational biomolecular and chemical engineer by training and most recently led the deployment of more than 20 programs that leveraged AI across several drug development functions at Johnson & Johnson’s Advanced Technologies Center of Excellence. This impacted $16 billion in yearly sales, reducing costs by 20 percent, and a 50 percent increase in reliability. His work has been recognized by the World Economic Forum, McKinsey & Company, and the National Academy of Engineering. Dr. Latshaw has a BSE in Chemical Engineering from Arizona State University, a Ph.D. in Chemical and Biomolecular Engineering from North Carolina State University, and a Master of Business Administration - MBA, Finance and Operations, from The Wharton School. Support the show
What this episode covers
Send us Fan Mail Dr. David Latshaw, Ph.D. is Co-Founder and CEO of BioPhy ( https://www.biophy.ai/ ), a Philadelphia based artificial intelligence company which has developed a set of platforms that provide quantitative metrics to drug company partners about what drugs and clinical trials will ultimately succeed. Dr. Latshaw is a computational biomolecular and chemical engineer by training and most recently led the deployment of more than 20 programs that leveraged AI across several drug deve...
NOW PLAYING
Dr. David Latshaw, Ph.D. - Co-Founder and CEO, BioPhy - Providing Practical AI For Drug Development
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m